These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2983076)

  • 1. Conformational analysis and active site modelling of angiotensin-converting enzyme inhibitors.
    Andrews PR; Carson JM; Caselli A; Spark MJ; Woods R
    J Med Chem; 1985 Mar; 28(3):393-9. PubMed ID: 2983076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies.
    Mayer D; Naylor CB; Motoc I; Marshall GR
    J Comput Aided Mol Des; 1987 Apr; 1(1):3-16. PubMed ID: 2851035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validated ligand mapping of ACE active site.
    Kuster DJ; Marshall GR
    J Comput Aided Mol Des; 2005 Aug; 19(8):609-15. PubMed ID: 16307311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformationally restricted inhibitors of angiotensin converting enzyme: synthesis and computations.
    Thorsett ED; Harris EE; Aster SD; Peterson ER; Snyder JP; Springer JP; Hirshfield J; Tristram EW; Patchett AA; Ulm EH
    J Med Chem; 1986 Feb; 29(2):251-60. PubMed ID: 3005569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystallographic studies of angiotensin converting enzyme inhibitors and analysis of preferred zinc coordination geometry.
    Hausin RJ; Codding PW
    J Med Chem; 1990 Jul; 33(7):1940-7. PubMed ID: 2362274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of conformationally constrained angiotensin-converting enzyme inhibitors.
    Weller HN; Gordon EM; Rom MB; Pluscec J
    Biochem Biophys Res Commun; 1984 Nov; 125(1):82-9. PubMed ID: 6095846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
    Fournié-Zaluski MC; Coric P; Turcaud S; Rousselet N; Gonzalez W; Barbe B; Pham I; Jullian N; Michel JB; Roques BP
    J Med Chem; 1994 Apr; 37(8):1070-83. PubMed ID: 8164250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,2-Cyclomethylenecarboxylic monoamide hydroxamic derivatives. A novel class of non-amino acid angiotensin converting enzyme inhibitors.
    Turbanti L; Cerbai G; Di Bugno C; Giorgi R; Garzelli G; Criscuoli M; Renzetti AR; Subissi A; Bramanti G; DePriest SA
    J Med Chem; 1993 Mar; 36(6):699-707. PubMed ID: 8459398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I.
    Michaud A; Williams TA; Chauvet MT; Corvol P
    Mol Pharmacol; 1997 Jun; 51(6):1070-6. PubMed ID: 9187274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of angiotensin I-converting enzyme (ACE)-containing follicles in the rat ovary during the estrous cycle and effects of ACE inhibitor on ovulation.
    Daud AI; Bumpus FM; Husain A
    Endocrinology; 1990 Jun; 126(6):2927-35. PubMed ID: 2161740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380.
    Corradi HR; Chitapi I; Sewell BT; Georgiadis D; Dive V; Sturrock ED; Acharya KR
    Biochemistry; 2007 May; 46(18):5473-8. PubMed ID: 17439247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
    Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC
    J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme: zinc- and inhibitor-binding stoichiometries of the somatic and testis isozymes.
    Ehlers MR; Riordan JF
    Biochemistry; 1991 Jul; 30(29):7118-26. PubMed ID: 1649623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical design of cilazapril.
    Attwood MR
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):133S-137S. PubMed ID: 2548550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of inhibitors on the coordination geometries of cadmium at the metal sites in angiotensin-I-converting enzyme.
    Carvalho E; Göthe PO; Bauer R; Danielsen E; Hemmingsen L
    Eur J Biochem; 1995 Dec; 234(3):780-5. PubMed ID: 8575435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of angiotensin converting enzyme by [3H]captopril binding.
    Strittmatter SM; Snyder SH
    Mol Pharmacol; 1986 Feb; 29(2):142-8. PubMed ID: 3005826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
    Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
    J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Angiotensin-converting enzyme inhibitors: recent therapeutic aspect].
    Shionoiri H; Shigemasa T; Takasaki I
    Nihon Rinsho; 1997 Aug; 55(8):2067-74. PubMed ID: 9284425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel ketomethylene inhibitors of angiotensin I-converting enzyme (ACE): inhibition and molecular modelling.
    Redelinghuys P; Nchinda AT; Chibale K; Sturrock ED
    Biol Chem; 2006 Apr; 387(4):461-6. PubMed ID: 16606345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.